123 related articles for article (PubMed ID: 36306820)
1. Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation.
Pons V; Garcia C; Tidten-Luksch N; Mac Sweeney A; Caroff E; Galés C; Riederer MA
Biochem Pharmacol; 2022 Dec; 206():115291. PubMed ID: 36306820
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor inverse agonist activity at the P2Y
Khalil J; Dimofte T; Roberts T; Keith M; Amaradasa K; Hindle MS; Bancroft S; Hutchinson JL; Naseem K; Johnson T; Mundell SJ
Br J Pharmacol; 2024 Jan; 181(1):21-35. PubMed ID: 37530222
[TBL] [Abstract][Full Text] [Related]
3. The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration.
Baumann M; Lack B; Guillaumat I; Murphy MJ; Riederer MA
Platelets; 2022 Jan; 33(1):147-156. PubMed ID: 33427002
[TBL] [Abstract][Full Text] [Related]
4. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
5. Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model.
Crescence L; Darbousset R; Caroff E; Hubler F; Riederer MA; Panicot-Dubois L; Dubois C
Thromb Res; 2021 Apr; 200():133-140. PubMed ID: 33610885
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y
Henrich A; Claussen CH; Dingemanse J; Krause A
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):735-747. PubMed ID: 33955698
[TBL] [Abstract][Full Text] [Related]
7. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Aungraheeta R; Conibear A; Butler M; Kelly E; Nylander S; Mumford A; Mundell SJ
Blood; 2016 Dec; 128(23):2717-2728. PubMed ID: 27694321
[TBL] [Abstract][Full Text] [Related]
8. Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y
Garcia C; Maurel-Ribes A; Nauze M; N'Guyen D; Martinez LO; Payrastre B; Sénard JM; Galés C; Pons V
Cell Mol Life Sci; 2019 Feb; 76(3):561-576. PubMed ID: 30406277
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
10. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Schilling U; Dingemanse J; Dobrow M; Baumann M; Riederer MA; Juif PE; Ufer M
Thromb Haemost; 2021 Jun; 121(6):755-766. PubMed ID: 33412611
[TBL] [Abstract][Full Text] [Related]
11. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
12. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
Zhang Y; Ye J; Hu L; Zhang S; Zhang SH; Li Y; Kunapuli SP; Ding Z
J Thromb Haemost; 2012 Oct; 10(10):2149-57. PubMed ID: 22906019
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
Storey RF; Gurbel PA; Ten Berg J; Bernaud C; Dangas GD; Frenoux JM; Gorog DA; Hmissi A; Kunadian V; James SK; Tanguay JF; Tran H; Trenk D; Ufer M; Van der Harst P; Van't Hof AWJ; Angiolillo DJ
Eur Heart J; 2020 Sep; 41(33):3132-3140. PubMed ID: 31994703
[TBL] [Abstract][Full Text] [Related]
14. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
15. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
16. Selatogrel, a novel P2Y
Milluzzo RP; Franchina GA; Capodanno D; Angiolillo DJ
Expert Opin Investig Drugs; 2020 Jun; 29(6):537-546. PubMed ID: 32396484
[TBL] [Abstract][Full Text] [Related]
17. Platelet inhibition by P2Y
Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
[TBL] [Abstract][Full Text] [Related]
18. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
19. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets.
Herfindal L; Nygaard G; Kopperud R; Krakstad C; Døskeland SO; Selheim F
Biochem Biophys Res Commun; 2013 Aug; 437(4):603-8. PubMed ID: 23850619
[TBL] [Abstract][Full Text] [Related]
20. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM
Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
